The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the ...
November 2, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading ...
About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the ...
This release fulfills the Company's October 20 announcement that next-round results on the expanded human-submitted dataset ...
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization ...
Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize ...
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary ...
Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in ...
In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the ...
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today ...
After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec ...
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results